The finding from an 18-month-long clinical trial strengthens hope that pharmacotherapy can break nicotine’s especially tenacious hold on people with serious mental illness such as bipolar disorder or schizophrenia.
Study patients with HIV–hepatitis C coinfection progressed to successive degrees of severity of liver fibrosis 9 years sooner than those infected with HCV alone. Further findings from the study suggest that suppressing HIV with antiretroviral medications may slow HCV-related liver fibrosis.
People with cannabis use disorder (CUD) are likely also to have social anxiety disorder (SAD), and comorbid SAD is associated with greater severity of cannabis-related problems. These findings highlight the importance of assessing CUD patients for SAD, as that disorder can be both a contributing cause and a consequence of CUD. Treating both disorders may be a key to helping patients recover from each.
People who use prescription opiates nonmedically are more likely to consider suicide than those who use these medications only appropriately or not at all. A recent NIDA-supported study also disclosed that the risk for suicidal thoughts remains elevated after cessation of use.
Intensive case management was more effective in increasing treatment engagement and reducing alcohol consumption among depressed participants than among those who were not depressed, according to a followup analysis of a substance abuse treatment study involving women on welfare.
A modified therapeutic community program designed by NIDA-supported researchers helped Colorado offenders with co-occurring substance use and mental health disorders re-enter their communities and avoid recidivism after release from prison.
Women with post-traumatic stress disorder (PTSD) who abused drugs responded better to substance abuse treatment after their PTSD symptoms improved, according to a recent study, which also found that reductions in substance abuse did not ease PTSD severity
April 2012 Dr. Volkow discusses NIDA’s efforts to develop effective antismoking treatments for populations with persistently high rates of smoking, such as people with psychiatric disorders, high school dropouts, and Native Americans.